You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2024

Claims for Patent: 8,591,941


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,591,941
Title:Transdermal drug delivery device including an occlusive backing
Abstract: A transdermal drug delivery system for the topical application of one or more active agents contained in one or more polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmission rate of the polymeric backing layer.
Inventor(s): Kanios; David (Miami, FL), Mantelle; Juan A. (Miami, FL), Nguyen; Viet (Miami, FL)
Assignee: Noven Pharmaceuticals, Inc. (Miami, FL)
Application Number:13/198,405
Patent Claims: 1. A transdermal drug delivery system for amphetamine comprising: (a) a pressure sensitive adhesive carrier layer comprising (i) an acrylic polymer and (ii) a therapeutically effective amount of amphetamine; and (b) a backing layer adjacent the carrier layer comprised of polymeric layers consisting of a polyester layer and a polyurethane layer.

2. The transdermal drug delivery system of claim 1, wherein the pressure sensitive adhesive carrier layer comprises a blend of a non-functional acrylic polymer and an acrylic polymer comprising functional groups.

3. The transdermal drug delivery system of claim 2, wherein the acrylic polymer comprising functional groups comprises amide groups.

4. The transdermal drug delivery system according to claim 1, wherein the amphetamine is selected from the group consisting of d-amphetamine, l-amphetamine, d,l-amphetamine, and mixtures thereof.

5. The transdermal drug delivery system according to claim 1, comprising from about 0.5% to about 15% by weight of amphetamine, based on the weight of the carrier layer.

6. The transdermal drug delivery system according to claim 1, comprising about 15% by weight of amphetamine, based on the weight of the carrier layer.

7. The transdermal drug delivery system according to claim 1, wherein the backing layer has a thickness of from about 0.2 mm to about 3 mm.

8. The transdermal drug delivery system according to claim 1, wherein said backing layer has a moisture vapor transmission rate of from 10 to about 100 g/m.sup.2/24 hrs.

9. The transdermal drug delivery system of claim 1, further comprising a release liner adjacent a surface of the carrier layer opposite the backing layer.

10. A transdermal drug delivery system for topical application of amphetamine comprising: (a) a pressure sensitive adhesive carrier layer consisting essentially of a blend of a non-functional acrylic polymer and an acrylic polymer comprising amide functional groups and a therapeutically effective amount of amphetamine; and (b) a backing layer adjacent the carrier layer comprised of polymeric layers consisting of a polyester layer and a polyurethane layer.

11. The transdermal drug delivery system of claim 10, further comprising a release liner adjacent a surface of the carrier layer opposite the backing layer.

12. A transdermal drug delivery system for topical application of amphetamine comprising: (a) a pressure sensitive adhesive carrier layer consisting of a blend of a non-functional acrylic polymer and an acrylic polymer comprising amide functional groups and a therapeutically effective amount of amphetamine; and (b) a backing layer adjacent the carrier layer comprised of polymeric layers consisting of a polyester layer and a polyurethane layer.

13. The transdermal drug delivery system of claim 12, further comprising a release liner adjacent a surface of the carrier layer opposite the backing layer.

14. A method for transdermally delivering amphetamine to a subject in need thereof comprising topically administering the transdermal drug delivery device according to claim 1 to said subject.

15. A method of producing the transdermal drug delivery system according to claim 13, comprising: (a) thoroughly and uniformly mixing a non-functional acrylic polymer and an acrylic polymer comprising amide functional groups and a therapeutically effective amount of amphetamine in an appropriate volatile solvent system; (b) casting said carrier layer onto a backing film comprised of polymeric layers consisting of a polyester layer and a polyurethane layer and exposing the cast carrier layer to elevated temperatures to remove volatile solvents; and (c) applying a release liner to the surface of the carrier layer opposite the backing layer to form the transdermal drug delivery composition.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.